Biotech ETFs rose ahead of the market due to the success of large-scale clinical trials of the melanoma vaccine jointly developed by Modena and MSD.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.